Cyclophosphamide
Neoplasm, Neuroepithelial
DNAtrix, Inc.Small moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Neoplasm, Neuroepithelial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin DNAtrix, Inc. | Phase 2 | B |
TASADENOTUREV DNAtrix, Inc. | Phase 2 | B |
Pembrolizumab DNAtrix, Inc. | Phase 2 | B |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →